Constab's New Tool To Treat Metastatic Colorectal, Other Cancers

Armen Hareyan's picture

Constab has further developed a drug candidate named Aimpila, that combines the Oncoshuttle platform with a direct apoptosis inducer capable of targeting and destroying cancer cells.

In seeking to: 1) maximize efficient delivery of a cytotoxic agent directly to cancer cells, and 2) reduce or eliminate the side effect burden on patients, Constab Pharmaceutical has developed a new, targeted drug-delivery technology aptly named, Oncoshuttle.

Aimpila has been investigated in animal models and in human pilot studies with various solid tumours. Preliminary study results released today at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO), show single agent Aimpila was well-tolerated and produced major objective responses in patients with liver metastatic colorectal cancer (mCRC).

This study investigated the single agent activity of Aimpila, a glycoside/alpha-fetoprotein (AFP) complex, in patients with documented late-stage liver mCRC. Patients received low dose Aimpila in an oral capsule, twice daily for 8 weeks, and were examined using CT scans before and after treatment.


Fifty percent (50%) of the 12 patients studied responded positively to treatment with Aimpila. Overall, 2 patients achieved a complete response, 1 achieved partial response, and 3 achieved stabilization of their disease, which in two cases lasted for two months or more. Of the remaining patients, 3 individuals experienced disease progression, and 3 were non-evaluable using study standards. One non-evaluable patient experienced nausea and vomiting.

"These are encouraging outcomes," remarks Dr. Mark Vincent, Medical Oncologist with the London Health Sciences Centre, in London, Ontario.

"People with metastatic colorectal cancer, despite the treatment advances already made, still face a limited life span. With an estimated 8,500 colorectal cancer deaths annually in Canada, and a staggering 56,000 in the U.S. - the SECOND LEADING cause of cancer death in the States - it is clear that effective treatment options constitute an ongoing unmet need."

"Aimpila appears to be well tolerated; at the same time the AFP receptor seems to be associated with a wide range of cancers, but not normal adult tissues. It is reasonable to suggest that quality of life could be maintained or improved with Aimpila. This drug complex certainly deserves further pre-clinical and bioavailability studies, followed by studies of larger patient groups in standardized, early phase clinical trials."

Some of the current anticancer drug therapies for the treatment of metastatic colorectal cancer offer improvements in survival time or median time to disease progression, yet remain encumbered by: